Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study)

Abstract Background The benefits of sodium glucose cotransporters 2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus include plasma glucose control, reduction in body weight and blood pressure, and low risk of hypoglycemia, although they may also cause genitourinary infections, polyuria,...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Hiroki Nakajima, Sadanori Okada, Takako Mohri, Eiichiro Kanda, Naoyuki Inaba, Yoko Hirasawa, Hiroaki Seino, Hisamoto Kuroda, Toru Hiyoshi, Tetsuji Niiya, Hitoshi Ishii
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMC 2018-03-01
Saila:Diabetology & Metabolic Syndrome
Gaiak:
Type 2 diabetes mellitus
Oral hypoglycemic agent
Sodium glucose cotransporters 2 inhibitors
SGLT2 inhibitors
Dapagliflozin
Treatment satisfaction
Sarrera elektronikoa:http://link.springer.com/article/10.1186/s13098-018-0313-x
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak